##common.pageHeaderLogo.altText##

Special article

Vol. 155 No. 3 (2025)

Conference report: Trends, new technologies and implications for dementia diagnostics, treatment and care in Switzerland

Cite this as:
Swiss Med Wkly. 2025;155:4017
Published
26.03.2025

Summary

Dementia diseases represent a major burden for the directly affected people, their relatives and modern society. Despite considerable efforts in recent years, early and accurate disease diagnosis and monitoring is still a challenge while no cure is available in most cases. New drugs, in particular disease-modifying therapies, and recent technological advancements offer promising perspectives. The integration of novel biomarkers, artificial intelligence and digital health tools has the potential to transform dementia care, making it more personalised, efficient and adapted to the living conditions and needs of older people. In November 2023, the 7th Dementia Summit convened a panel of experts from geriatrics, neurology, neuropsychology, psychiatry, ethics as well as general medicine to discuss interdisciplinary challenges, advancements and their implications for the future of dementia care in Switzerland. The conference underscored the importance of a multidisciplinary approach to successfully integrate new technologies in both clinical-translational research and dementia prevention, diagnosis and care. While recent innovations represent major steps forward, their implementation also comes with important challenges including questions on healthcare system preparedness and adaptation, ethical aspects, technology literacy, acceptance and appropriate use.

References

  1. Alzheimer Schweiz. Demenz in der Schweiz 2024. Zahlen und Fakten. 2024; Available from: https://www.alzheimer-schweiz.ch/fileadmin/dam/Alzheimer_Schweiz/Dokumente/Ueber_Demenz/Zahlen-Fakten/Factsheet_DemenzCH_2024_DE.pdf
  2. Kheirouri S, Alizadeh M. MIND diet and cognitive performance in older adults: a systematic review. Crit Rev Food Sci Nutr. 2022;62(29):8059–77. doi: https://doi.org/10.1080/10408398.2021.1925220
  3. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun;385(9984):2255–63. doi: https://doi.org/10.1016/S0140-6736(15)60461-5
  4. Barnes LL, Dhana K, Liu X, Carey VJ, Ventrelle J, Johnson K, et al. Trial of the MIND Diet for Prevention of Cognitive Decline in Older Persons. N Engl J Med. 2023 Aug;389(7):602–11. doi: https://doi.org/10.1056/NEJMoa2302368
  5. Gates EJ, Bernath AK, Klegeris A. Modifying the diet and gut microbiota to prevent and manage neurodegenerative diseases. Rev Neurosci. 2022 Mar;33(7):767–87. doi: https://doi.org/10.1515/revneuro-2021-0146
  6. Xiao S, Chan P, Wang T, Hong Z, Wang S, Kuang W, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimers Res Ther. 2021 Mar;13(1):62. doi: https://doi.org/10.1186/s13195-021-00795-7
  7. Grammatikopoulou MG, Goulis DG, Gkiouras K, Theodoridis X, Gkouskou KK, Evangeliou A, et al. To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease. Adv Nutr. 2020 Nov;11(6):1583–602. doi: https://doi.org/10.1093/advances/nmaa073
  8. Fortier M, Castellano CA, St-Pierre V, Myette-Côté É, Langlois F, Roy M, et al. A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. Alzheimers Dement. 2021 Mar;17(3):543–52. doi: https://doi.org/10.1002/alz.12206
  9. Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol. 2006 Sep;63(9):1312–7. doi: https://doi.org/10.1001/archneur.63.9.1312
  10. Rosano C, Newman A, Santanasto A, Zhu X, Goodpaster B, Miljkovic I. Increase in skeletal muscular adiposity and cognitive decline in a biracial cohort of older men and women. J Am Geriatr Soc. 2023 Sep;71(9):2759–68. doi: https://doi.org/10.1111/jgs.18419
  11. Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013 Aug;14(8):542–59. doi: https://doi.org/10.1016/j.jamda.2013.05.021
  12. Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2015 Sep;16(9):740–7. doi: https://doi.org/10.1016/j.jamda.2015.05.021
  13. Frisoni GB, Altomare D, Ribaldi F, Villain N, Brayne C, Mukadam N, et al. Dementia prevention in memory clinics: recommendations from the European task force for brain health services. Lancet Reg Health Eur. 2023 Jan;26:100576. doi: https://doi.org/10.1016/j.lanepe.2022.100576
  14. Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024 Aug;404(10452):572–628. doi: https://doi.org/10.1016/S0140-6736(24)01296-0
  15. Ballesteros S, Kraft E, Santana S, Tziraki C. Maintaining older brain functionality: A targeted review. Neurosci Biobehav Rev. 2015 Aug;55:453–77. doi: https://doi.org/10.1016/j.neubiorev.2015.06.008
  16. Meng X, Fang S, Zhang S, Li H, Ma D, Ye Y, et al. Multidomain lifestyle interventions for cognition and the risk of dementia: A systematic review and meta-analysis. Int J Nurs Stud. 2022 Jun;130:104236. doi: https://doi.org/10.1016/j.ijnurstu.2022.104236
  17. Brioschi Guevara A, Bieler M, Altomare D, Berthier M, Csajka C, Dautricourt S, et al. Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6. Alzheimers Res Ther. 2021 Oct;13(1):172. doi: https://doi.org/10.1186/s13195-021-00844-1
  18. Sokolov AA, Collignon A, Bieler-Aeschlimann M. Serious video games and virtual reality for prevention and neurorehabilitation of cognitive decline because of aging and neurodegeneration. Curr Opin Neurol. 2020 Apr;33(2):239–48. doi: https://doi.org/10.1097/WCO.0000000000000791
  19. Belleville S, Cuesta M, Bieler-Aeschlimann M, Giacomino K, Widmer A, Mittaz Hager AG, et al. Rationale and protocol of the StayFitLonger study: a multicentre trial to measure efficacy and adherence of a home-based computerised multidomain intervention in healthy older adults. BMC Geriatr. 2020 Aug;20(1):315. doi: https://doi.org/10.1186/s12877-020-01709-2
  20. Belleville S, Cuesta M, Bieler-Aeschlimann M, Giacomino K, Widmer A, Mittaz Hager AG, et al. Pre-frail older adults show improved cognition with StayFitLonger computerized home-based training: a randomized controlled trial. Geroscience. 2023 Apr;45(2):811–22. doi: https://doi.org/10.1007/s11357-022-00674-5
  21. Leidi-Maimone B, Notter-Bielser ML, Laouadi MH, Perrin S, Métraux H, Damian D, et al. How non-drug interventions affect the quality of life of patients suffering from progressive cognitive decline and their main caregiver. Aging (Albany NY). 2020 Jun;12(11):10754–71. doi: https://doi.org/10.18632/aging.103291
  22. Chatton P, Martins M, Carlier S, Bieler-Aeschlimann M. [Long COVID : which neuropsychological intervention? The example applied at the Leenaards Memory Centre]. Rev Med Suisse. 2023 May;19(827):979–83. doi: https://doi.org/10.53738/REVMED.2023.19.827.979
  23. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al.; Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008 Feb;23(2):170–7. doi: https://doi.org/10.1002/gps.1858
  24. Sheikh F, Ismail Z, Mortby ME, Barber P, Cieslak A, Fischer K, et al.; PROMPT registry investigators. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. Int Psychogeriatr. 2018 Feb;30(2):233–44. doi: https://doi.org/10.1017/S104161021700151X
  25. Spiegl K, Luttenberger K, Graessel E, Becker L, Scheel J, Pendergrass A. Predictors of institutionalization in users of day care facilities with mild cognitive impairment to moderate dementia. BMC Health Serv Res. 2021 Sep;21(1):1009. doi: https://doi.org/10.1186/s12913-021-07017-8
  26. Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015 May;172(5):460–5. doi: https://doi.org/10.1176/appi.ajp.2014.14040480
  27. Showraki A, Murari G, Ismail Z, Barfett JJ, Fornazzari L, Munoz DG, et al. Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease/Mild Cognitive Impairment: A Systematic Review. J Alzheimers Dis. 2019;71(2):477–501. doi: https://doi.org/10.3233/JAD-190365
  28. Bloniecki V, Zetterberg H, Aarsland D, Vannini P, Kvartsberg H, Winblad B, et al. Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration? Alzheimers Res Ther. 2020 Nov;12(1):153. doi: https://doi.org/10.1186/s13195-020-00718-y
  29. Rabl M, et al. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression. Res Sq, 2024 Mar 22:rs.3.rs-4116836. doi: 10.21203/rs.3.rs-4116836/v1
  30. Rabl M, Clark C, Dayon L, Bowman GL, Popp J. Blood plasma protein profiles of neuropsychiatric symptoms and related cognitive decline in older people. J Neurochem. 2023 Jan;164(2):242–54. doi: https://doi.org/10.1111/jnc.15715
  31. Mroczek M, Clark C, Dayon L, Bowman GL, Popp J. Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer’s Disease. Cells. 2022 Mar;11(6):1030. doi: https://doi.org/10.3390/cells11061030
  32. Clark C, Richiardi J, Maréchal B, Bowman GL, Dayon L, Popp J. Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people. J Neuroinflammation. 2022 May;19(1):127. doi: https://doi.org/10.1186/s12974-022-02473-3
  33. Rabl M, Clark C, Dayon L, Popp J; Alzheimer’s Disease Neuroimaging Initiative. Neuropsychiatric symptoms in cognitive decline and Alzheimer’s disease: biomarker discovery using plasma proteomics. J Neurol Neurosurg Psychiatry. 2024 Sep;•••:jnnp-2024-333819. 10.1136/jnnp-2024-333819
  34. Jotterand F, et al. (Jotterand F, Ienca M, Wangmo T, Elger B, editors). Intelligent assistive technologies for dementia: clinical, ethical, social, and regulatory implications. USA: Oxford University Press; 2019. doi: https://doi.org/10.1093/med/9780190459802.001.0001
  35. Ienca M, Fabrice J, Elger B, Caon M, Scoccia Pappagallo A, Kressig RW, et al. Intelligent assistive technology for Alzheimer’s disease and other dementias: a systematic review. J Alzheimers Dis. 2017;56(4):1301–40. doi: https://doi.org/10.3233/JAD-161037
  36. Ienca M, Jotterand F, Vică C, Elger B. Social and assistive robotics in dementia care: ethical recommendations for research and practice. Int J Soc Robot. 2016;8(4):565–73. doi: https://doi.org/10.1007/s12369-016-0366-7
  37. Javeed A, Dallora AL, Berglund JS, Ali A, Ali L, Anderberg P. Machine Learning for Dementia Prediction: A Systematic Review and Future Research Directions. J Med Syst. 2023 Feb;47(1):17. doi: https://doi.org/10.1007/s10916-023-01906-7
  38. Ienca M, Wangmo T, Jotterand F, Kressig RW, Elger B. Ethical design of intelligent assistive technologies for dementia: a descriptive review. Sci Eng Ethics. 2018 Aug;24(4):1035–55. doi: https://doi.org/10.1007/s11948-017-9976-1
  39. Cote, A.C., et al., Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis. Front Med (Lausanne), 2021 Jan 11:7:501104. doi: 10.3389/fmed.2020.501104. eCollection 2020.
  40. Buchman DZ, Wadhawan S. A global vision for neuroethics needs more social justice: brain imaging, chronic pain, and population health inequalities. AJOB Neurosci. 2019;10(3):130–2. doi: https://doi.org/10.1080/21507740.2019.1632966
  41. Goodman MS, Ackermann N, Bowen DJ, Panel D, Thompson VS. Reaching consensus on principles of stakeholder engagement in research. Prog Community Health Partnersh. 2020;14(1):117–27. doi: https://doi.org/10.1353/cpr.2020.0014
  42. Wangmo T, Lipps M, Kressig RW, Ienca M. Ethical concerns with the use of intelligent assistive technology: findings from a qualitative study with professional stakeholders. BMC Med Ethics. 2019 Dec;20(1):98. doi: https://doi.org/10.1186/s12910-019-0437-z
  43. Ienca M, Schneble C, Kressig RW, Wangmo T. Digital health interventions for healthy ageing: a qualitative user evaluation and ethical assessment. BMC Geriatr. 2021 Jul;21(1):412. doi: https://doi.org/10.1186/s12877-021-02338-z
  44. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. American Psychiatric Publishing, Inc.; 2013. 10.1176/appi.books.9780890425596
  45. Romero HR, Monsch AU, Hayden KM, Plassman BL, Atkins AS, Keefe RS, et al. TOMMORROW neuropsychological battery: german language validation and normative study. Alzheimers Dement (N Y). 2018 Jul;4(1):314–23. 10.1016/j.trci.2018.06.009
  46. Chen C, Ding S, Wang J. Digital health for aging populations. Nat Med. 2023 Jul;29(7):1623–30. doi: https://doi.org/10.1038/s41591-023-02391-8
  47. Berron D, Glanz W, Clark L, Basche K, Grande X, Güsten J, et al. A remote digital memory composite to detect cognitive impairment in memory clinic samples in unsupervised settings using mobile devices. NPJ Digit Med. 2024 Mar;7(1):79. doi: https://doi.org/10.1038/s41746-024-00999-9
  48. Cognat E, Mouton Liger F, Troussière AC, Wallon D, Dumurgier J, Magnin E, et al.; ePLM network. What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open. 2019 May;9(5):e026380. doi: https://doi.org/10.1136/bmjopen-2018-026380
  49. Rabinovici GD, Carrillo MC, Apgar C, Gareen IF, Gutman R, Hanna L, et al. Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA Neurol. 2023 Nov;80(11):1166–73. doi: https://doi.org/10.1001/jamaneurol.2023.3490
  50. Popp J, Georgescu D, Bürge M, Mundwiler-Pachlatko E, Bernasconi L, Felbecker A. [Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]. Rev Med Suisse. 2022 Dec;18(808):2400–5. 10.53738/REVMED.2022.18.808.2400
  51. Popp, J., et al., [Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]. Praxis (Bern 1994), 2022. 111(13): p. 738-744. doi: 10.1024/1661-8157/a003913
  52. Popp J, Oikonomidi A, Tautvydaitė D, Dayon L, Bacher M, Migliavacca E, et al. Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults. Brain Behav Immun. 2017 May;62:203–11. doi: https://doi.org/10.1016/j.bbi.2017.01.020
  53. Clark C, Gholam M, Zullo L, Kerksiek A, Castelao E, von Gunten A, et al. Plant sterols and cholesterol metabolism are associated with five-year cognitive decline in the elderly population. iScience. 2023 Apr;26(6):106740. doi: https://doi.org/10.1016/j.isci.2023.106740
  54. Clark C, Dayon L, Masoodi M, Bowman GL, Popp J. An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease. Alzheimers Res Ther. 2021 Apr;13(1):71. doi: https://doi.org/10.1186/s13195-021-00814-7
  55. Clark C, Rabl M, Dayon L, Popp J. The promise of multi-omics approaches to discover biological alterations with clinical relevance in Alzheimer’s disease. Front Aging Neurosci. 2022 Dec;14:1065904. doi: https://doi.org/10.3389/fnagi.2022.1065904
  56. Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer’s disease in clinical practice and trials. Nat Aging. 2023 May;3(5):506–19. doi: https://doi.org/10.1038/s43587-023-00403-3
  57. Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022 Dec;79(12):1250–9. doi: https://doi.org/10.1001/jamaneurol.2022.3392
  58. Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer’s disease. EMBO Mol Med. 2022 Jan;14(1):e14408. doi: https://doi.org/10.15252/emmm.202114408
  59. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023 Jan;388(1):9–21. doi: https://doi.org/10.1056/NEJMoa2212948
  60. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al.; TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug;330(6):512–27. doi: https://doi.org/10.1001/jama.2023.13239
  61. Sperling R. Lecanemab for the Treatment of Early Alzheimer’s Disease: The Extension of Efficacy Results from Clarity AD. in 16 th Clinical Trials on Alzheimer’s Disease (CTAD). 2023. Boston, MA (USA)
  62. O’Gorman J. Pooled ENGAGE/EMERGE integrated placebo-controlled period and long-term extension (LTE) topline results: slower clinical progression at Week 134 in aducanumab-treated patients that became amyloid PET negative at Week 78. in 16 th Clinical Trials on Alzheimer’s Disease (CTAD). 2023. Boston, MA (USA)
  63. Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022 Jan;79(1):13–21. doi: https://doi.org/10.1001/jamaneurol.2021.4161
  64. Honig LS, Barakos J, Dhadda S, Kanekiyo M, Reyderman L, Irizarry M, et al. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer’s disease. Alzheimers Dement (N Y). 2023 Mar;9(1):e12377. doi: https://doi.org/10.1002/trc2.12377
  65. Yu C, Sommerlad A, Sakure L, Livingston G. Socially assistive robots for people with dementia: systematic review and meta-analysis of feasibility, acceptability and the effect on cognition, neuropsychiatric symptoms and quality of life. Ageing Res Rev. 2022 Jun;78:101633. doi: https://doi.org/10.1016/j.arr.2022.101633
  66. Wright J. Inside Japan’s long experiment in automating elder care. 2023; Available from: https://www.technologyreview.com/2023/01/09/1065135/japan-automating-eldercare-robots/
  67. Bate GL, Kirk C, Rehman RZ, Guan Y, Yarnall AJ, Del Din S, et al. The Role of Wearable Sensors to Monitor Physical Activity and Sleep Patterns in Older Adult Inpatients: A Structured Review. Sensors (Basel). 2023 May;23(10):4881. 10.3390/s23104881
  68. Cortés OL, Piñeros H, Aya PA, Sarmiento J, Arévalo I. Systematic review and meta-analysis of clinical trials: in-hospital use of sensors for prevention of falls. Medicine (Baltimore). 2021 Oct;100(41):e27467. doi: https://doi.org/10.1097/MD.0000000000027467
  69. Owens AP, Krebs C, Kuruppu S, Brem AK, Kowatsch T, Aarsland D, et al. Broadened assessments, health education and cognitive aids in the remote memory clinic. Front Public Health. 2022 Dec;10:1033515. doi: https://doi.org/10.3389/fpubh.2022.1033515
  70. Brill E, Klusmann-Weisskopf V, Klöppel S. Wenn Werte motivieren. Schweiz Arzteztg. 2023;104(40):34–5.
  71. Covinsky KE, Pierluissi E, Johnston CB. Hospitalization-associated disability: “She was probably able to ambulate, but I’m not sure”. JAMA. 2011 Oct;306(16):1782–93. doi: https://doi.org/10.1001/jama.2011.1556
  72. Adams D, Wolfe AJ, Warren J, Laberge A, Richards AC, Herzer K, et al. Initial Findings From an Acute Hospital Care at Home Waiver Initiative. JAMA Health Forum. 2023 Nov;4(11):e233667. doi: https://doi.org/10.1001/jamahealthforum.2023.3667
  73. Shepperd S, Iliffe S, Doll HA, Clarke MJ, Kalra L, Wilson AD, et al. Admission avoidance hospital at home. Cochrane Database Syst Rev. 2016 Sep;9(9):CD007491.
  74. Shepperd S, Butler C, Cradduck-Bamford A, Ellis G, Gray A, Hemsley A, et al. Is Comprehensive Geriatric Assessment Admission Avoidance Hospital at Home an Alternative to Hospital Admission for Older Persons?: A Randomized Trial. Ann Intern Med. 2021 Jul;174(7):889–98. doi: https://doi.org/10.7326/M20-5688
  75. Bates DW, Levine DM, Salmasian H, Syrowatka A, Shahian DM, Lipsitz S, et al. The Safety of Inpatient Health Care. N Engl J Med. 2023 Jan;388(2):142–53. doi: https://doi.org/10.1056/NEJMsa2206117
  76. England N. NHS delivers 10,000 virtual ward beds target with hundreds of thousands of patients treated at home. 2023 oct 12; Available from: https://www.england.nhs.uk/2023/10/nhs-delivers-10000-virtual-ward-beds-target-with-hundreds-of-thousands-of-patients-treated-at-home/
  77. Ouchi K, Liu S, Tonellato D, Keschner YG, Kennedy M, Levine DM. Home hospital as a disposition for older adults from the emergency department: benefits and opportunities. J Am Coll Emerg Physicians Open. 2021 Jul;2(4):e12517. doi: https://doi.org/10.1002/emp2.12517
  78. Chu JN, Kaplan C, Lee JS, Livaudais-Toman J, Karliner L. Increasing Telehealth Access to Care for Older Adults During the COVID-19 Pandemic at an Academic Medical Center: Video Visits for Elders Project (VVEP). Jt Comm J Qual Patient Saf. 2022 Mar;48(3):173–9. doi: https://doi.org/10.1016/j.jcjq.2021.11.006
  79. Huang G, Oteng SA. Gerontechnology for better elderly care and life quality: a systematic literature review. Eur J Ageing. 2023 Jun;20(1):27. doi: https://doi.org/10.1007/s10433-023-00776-9
  80. Lindqvist E, PerssonVasiliou A, Hwang AS, Mihailidis A, Astelle A, Sixsmith A, et al. The contrasting role of technology as both supportive and hindering in the everyday lives of people with mild cognitive deficits: a focus group study. BMC Geriatr. 2018 Aug;18(1):185. doi: https://doi.org/10.1186/s12877-018-0879-z
  81. Sixsmith A, Mihailidis A, Simeonov D. Aging and Technology: Taking the Research into the Real World. Public Policy Aging Rep. 2017;27(2):74–8. doi: https://doi.org/10.1093/ppar/prx007
  82. Seifert A, Charness N. Digital transformation of everyday lives of older Swiss adults: use of and attitudes toward current and future digital services. Eur J Ageing. 2022 Jan;19(3):729–39. doi: https://doi.org/10.1007/s10433-021-00677-9
  83. Dwivedi YK, Rana NP, Jeyaraj A, Clement M, Williams MD. Re-examining the Unified Theory of Acceptance and Use of Technology (UTAUT): Towards a Revised Theoretical Model. Inf Syst Front. 2019;21(3):719–34. doi: https://doi.org/10.1007/s10796-017-9774-y
  84. Ienca M, Kressig RW, Jotterand F, Elger B. Proactive Ethical Design for Neuroengineering, Assistive and Rehabilitation Technologies: the Cybathlon Lesson. J Neuroeng Rehabil. 2017 Nov;14(1):115. doi: https://doi.org/10.1186/s12984-017-0325-z